Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06557291 · ClinicalTrials.gov registry record
Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 38
- Enrollment target
NCT06557291 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 38 participants.
The verdict
NCT06557291 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
This was a retrospective chart review study of all proto-oncogene B-Raf (BRAF) V600-mutated patients who received adjuvant checkpoint inhibitor (CPI) therapy, relapsed locoregionally or distantly, and were again resected to no evidence of disease (NED) and treated with adjuvant dabrafenib and trametinib (dab/tram) combination therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-10-04 |
| Est. Completion | 2023-11-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06557291
The ClinicalTrials.gov registry entry for NCT06557291 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06557291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06557291 about?
NCT06557291 is a clinical study titled "Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma". This was a retrospective chart review study of all proto-oncogene B-Raf (BRAF) V600-mutated patients who received adjuvant checkpoint inhibitor (CPI) therapy, relapsed locoregionally or distantly, and were again resected to no evidence of disease (NED) and treated with adjuvant dabrafenib and tramet...
What is the current status of trial NCT06557291?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2022-10-04. Estimated completion is 2023-11-16.
Who is sponsoring clinical trial NCT06557291?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.